Musser Margaret L, Meritet Danielle, Viall Austin K, Choi Eunju, Willcox Jennifer L, Mathews Kyle G
Veterinary Clinical Sciences, Iowa State University, College of Veterinary Medicine, Ames, Iowa, USA.
Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.
Vet Comp Oncol. 2025 Mar;23(1):52-61. doi: 10.1111/vco.13025. Epub 2024 Nov 4.
Data regarding the outcome of canine rib chondrosarcoma is sparse and varied. While grade of tumour is associated with outcome for canine appendicular chondrosarcoma, the association of grade with outcome for canine rib chondrosarcoma is unclear. This study aimed to correlate the grade of canine rib chondrosarcoma with median survival time. Retrospectively, cases of primary rib chondrosarcoma were identified, and tumours were graded based on a 3-tier adapted human grading scheme. Twenty-two patients were included in the survival analysis. The median survival time was 1427 days (range: 27-3354 days). This was not significantly different for patients with grade I versus II versus III (p = 0.82), grade I-II versus III (p = 0.34), or grade I versus II-III (p = 0.49). No variables assessed including age, weight, tumour location (cranial vs. caudal thorax; left vs. right hemithorax), tumour location on rib (proximal, middle, and distal), radiographic appearance (lytic, proliferative, or mixed), elevated serum alkaline phosphatase activity, grade, grade specific histologic features (matrix production, architecture, pleomorphism, cellularity, necrosis, and total score), adjunct therapy post-surgical excision, development of metastatic disease post-surgery, or local recurrence post-surgery were found to impact the risk of death due to chondrosarcoma. In this limited group of patients, the grading scheme reported here, and the other variables assessed did not appear to offer additional prognostic information. However, this data must be interpreted considering the small sample size and thus low statistical power. Additional studies are needed to determine the true impact of grade on outcome for canine rib chondrosarcomas.
关于犬肋骨软骨肉瘤预后的数据稀少且各不相同。虽然肿瘤分级与犬附肢软骨肉瘤的预后相关,但犬肋骨软骨肉瘤分级与预后的关联尚不清楚。本研究旨在将犬肋骨软骨肉瘤的分级与中位生存时间相关联。回顾性地确定原发性肋骨软骨肉瘤病例,并根据一种经过调整的人类三级分级方案对肿瘤进行分级。22例患者纳入生存分析。中位生存时间为1427天(范围:27 - 3354天)。I级、II级与III级患者(p = 0.82)、I - II级与III级患者(p = 0.34)或I级与II - III级患者(p = 0.49)之间的中位生存时间无显著差异。所评估的变量包括年龄、体重、肿瘤位置(胸廓头侧与尾侧;左半胸与右半胸)、肋骨上的肿瘤位置(近端、中段和远端)、影像学表现(溶骨性、增殖性或混合型)、血清碱性磷酸酶活性升高、分级、分级特异性组织学特征(基质产生、结构、多形性、细胞密度、坏死和总分)、手术切除后的辅助治疗、手术后转移性疾病的发生或手术后局部复发,均未发现会影响软骨肉瘤导致的死亡风险。在这一有限的患者群体中,本文报告的分级方案以及所评估的其他变量似乎并未提供额外的预后信息。然而,考虑到样本量小以及因此统计效力低,必须对这些数据进行解读。需要进一步的研究来确定分级对犬肋骨软骨肉瘤预后的真正影响。